Compare LSCC & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LSCC | HALO |
|---|---|---|
| Founded | 1983 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 7.4B |
| IPO Year | 1989 | N/A |
| Metric | LSCC | HALO |
|---|---|---|
| Price | $74.38 | $67.61 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 12 |
| Target Price | ★ $76.18 | $73.33 |
| AVG Volume (30 Days) | 1.7M | ★ 2.2M |
| Earning Date | 02-09-2026 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 56.68 |
| EPS | 0.20 | ★ 4.74 |
| Revenue | $494,889,000.00 | ★ $1,242,852,000.00 |
| Revenue This Year | $4.23 | $34.83 |
| Revenue Next Year | $21.23 | $24.84 |
| P/E Ratio | $375.93 | ★ $14.56 |
| Revenue Growth | N/A | ★ 31.19 |
| 52 Week Low | $34.69 | $47.50 |
| 52 Week High | $81.23 | $79.50 |
| Indicator | LSCC | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 51.70 | 52.99 |
| Support Level | $71.27 | $67.95 |
| Resistance Level | $77.00 | $69.48 |
| Average True Range (ATR) | 2.24 | 1.61 |
| MACD | -0.36 | 0.58 |
| Stochastic Oscillator | 35.69 | 77.29 |
Lattice Semiconductor Corp is a developer of semiconductor technology that it distributes through products, solutions, and licenses. The company reaches its customers through consumer, communications, and industrial markets. The company has one operating segment namely the core Lattice business that includes silicon-based and silicon-enabling products, evaluation boards, development hardware, and related intellectual property licensing, services, and sales. The products of the company are offered globally; and, the majority of sales are derived from customers in Asia. It also has its presence in Americas and Europe.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.